Live Breaking News & Updates on Leukemia Research Program

Stay updated with breaking news from Leukemia research program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies. ....

Jeffery Auletta , Ohio State University College Of Medicine , Ohio State University , Ohio State University Comprehensive Cancer Center , Leukemia Research Program , Infectious Diseases , Nationwide Children , Ohio State University College , Regenerative Medicine , Cell Based Therapies , Transplantation And Cellular Therapy Meetings , Onclive Tv ,

Pirtobrutinib Demonstrates Durable Efficacy in Covalent BTK Inhibitor–Pretreated CLL/SLL

Pirtobrutinib continued to showcase clinically meaningful efficacy in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had prior exposure to a covalent BTK inhibitor. ....

Pirtobrutinib Jaypirca , Jennifera Woyach , Division Of Hematology , Leukemia Research Program , Ohio State University , Ohio State University Comprehensive Cancer Center , Patients With Chronic Lymphocytic Leukemia , Small Lymphocytic Lymphoma , Bruin Study , The Ohio State University Comprehensive Cancer Center ,

University succeeds in first human trial of new drug to combat relapsed blood cancer

University succeeds in first human trial of new drug to combat relapsed blood cancer
thelantern.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelantern.com Daily Mail and Mail on Sunday newspapers.

United States , Ohio State University , Jennifer Woyach , Ohio State University Comprehensive Cancer Center , Leukemia Research Program , Mackenzie Shanklin , Ohio State ,

First in human trial of new drug raises hopes

<p>A new targeted drug, studied by researchers at <a href="https://cancer.osu.edu/">The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James)</a>, may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments.</p>
....

United States , University Of Cincinnati , Ohio State University , Lindsey Granlund , Mohammed Farooqui , Brian Schwartz , Sudharshan Eathiraj , Jennifer Woyach , Arthurg James , Elizabeth Muhowski , Ian Flinn , Deborah Stephens , Johnc Byrd , Wayne Wang , Sean Reiff , Lyndsey Szuszkiewicz , Razi Ghori , Feng Chai , Method Of Research , Merck Co , Leukemia Research Program , Sarah Cannon Research Institute , Huntsman Cancer Institute , Richardj Solove Research Institute , Ohio State University Comprehensive Cancer Center , University Of Cincinnati College Medicine ,

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments. ....

United States , Elizabeth Muhowski , Mohammed Farooqui , Johnc Byrd , Ian Flinn , Feng Chai , Lindsey Granlund , Arthurg James , Sudharshan Eathiraj , Sean Reiff , Brian Schwartz , Lily Ramsey , Wayne Wang , Lyndsey Szuszkiewicz , Deborah Stephens , Jennifer Woyach , Razi Ghori , Ohio State University Comprehensive Cancer Center , Merck Co , University Of Cincinnati College Medicine , Huntsman Cancer Institute , Leukemia Research Program , Arqule Inc , Richardj Solove Research Institute , Sarah Cannon Research Institute , Cancer Hospital ,